A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the ...

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile ...

“ PD-1 Non-Small Cell Lung Cancer Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the ...

NuCana (NCNA) presented data at the European Society for Medical Oncology Congress 2025, ESMO, on a new model system investigating the synergistic ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today presented compelling primary results from the ...

Complete response rate was 37%, and post-hoc end point of objective response rate was 89%. HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent ...

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.

Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial. This is an ASCO Meeting ...